MEK inhibitor, PD98059, promotes breast cancer cell migration by inducing β-catenin nuclear accumulation

Area of Science:

• Oncology
• Molecular Biology
• Cell Signaling

Background:

• Aberrant RAF/MEK/ERK pathway activation is implicated in breast cancer development.
• MEK inhibitors are investigated as a breast cancer treatment, but clinical efficacy is limited.
• The precise mechanisms underlying MEK inhibitor ineffectiveness in breast cancer remain unclear.

Purpose of the Study:

• To evaluate the anticancer effects of MEK inhibitor PD98059 on human breast cancer cell lines (MCF-7 and MDA-MB-231).
• To investigate the underlying mechanisms of PD98059 action, particularly concerning cell proliferation and migration.
• To explore the potential role of β-catenin and EGFR signaling in mediating PD98059 effects.

Main Methods:

• Treatment of MCF-7 and MDA-MB-231 cells with varying concentrations and durations of PD98059.
• Assessment of cell proliferation using dose- and time-dependent assays.
• Evaluation of cell migration using migration assays.
• Analysis of β-catenin nuclear translocation and EGFR signaling activation.

Main Results:

• PD98059 demonstrated dose- and time-dependent antiproliferative effects on both breast cancer cell lines.
• Conversely, PD98059 significantly promoted cell migration in MCF-7 and MDA-MB-231 cells.
• Enhanced migration was dependent on PD98059-induced β-catenin nuclear translocation.
• PD98059 activated EGFR signaling, leading to increased nuclear β-catenin.

Conclusions:

• MEK inhibitor PD98059 exhibits dual effects on breast cancer cells, inhibiting proliferation while promoting migration.
• The pro-migratory effect is mediated through EGFR signaling and subsequent β-catenin nuclear translocation.
• These findings offer a potential explanation for the limited survival benefit observed with MEK inhibitors in breast cancer treatment.
• Understanding this mechanism could guide the development of more effective breast cancer therapies.